Furthermore, the detection of TIM-3 in the serum of all HCC patients could indicate that TIM-3/gal-9 pathway plays a more critical role than PD-1/PD-L1 axis in HCC immunity and may be a potential target for future HCC treatments. This evidence concerns the gene CD274 and hepatocellular carcinoma.